| Trial ID: | L0390 |
| Source ID: | NCT04806750
|
| Associated Drug: |
Emricasan
|
| Title: |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Cirrhosis;Portal Hypertension;Non-alcoholic Steatohepatitis
|
| Interventions: |
Drug: Emricasan;Drug: Placebo
|
| Outcome Measures: |
Mean Change in Hepatic Venous Pressure Gradient (HVPG)Improvement of HVPG response using a 20% reduction from baseline;Caspase 3/7;Alanine aminotransferase (ALT);The Number of Subjects with Treatment Emergent Adverse Events
|
| Sponsor/Collaborators: |
Histogen
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 2
|
| Enrollment: |
263
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
|
| Start Date: |
17/03/2021
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
29 March 2021
|
| Locations: |
--
|
| URL: |
https://clinicaltrials.gov/show/NCT04806750
|
